Efficacy and Safety of Different Dual Antithrombotic Therapies in Patients with Lower Extremity Arteriosclerosis Obliterans
10.3870/j.issn.1004-0781.2024.12.019
- VernacularTitle:不同双联抗栓方案治疗下肢动脉硬化闭塞症疗效及安全性
- Author:
Zhou HAN
1
;
Yepeng ZHANG
;
Huanyu NI
;
Xiaoqiang LI
;
Baoyan WANG
Author Information
1. 南京大学医学院附属鼓楼医院 药学部,南京 210008
- Keywords:
Clopidogrel;
Cilostazol;
Rivaroxaban;
Lower extremity arteriosclerosis obliterans;
Dual antithrombotic therapy
- From:
Herald of Medicine
2024;43(12):1991-1996
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of different antiplatelet drugs combined with rivaroxaban in patients with lower extremity arteriosclerosis obliterans.Methods The clinical data of patients with lower extremity arteriosclerosis obliterans who were symptomatic and underwent surgical treatment at the Vascular Surgery Department of Nanjing Drum Tower Hospital from January 2018 to December 2021 were retrospectively analyzed.According to the different antiplatelet medications taken by patients,patients were categorized into aspirin group,clopidogrel group and cilostazol group.Baseline data of patients were collected,and patients were followed up and the incidence of major adverse cardiovascular events,major adverse limb events,major bleeding and clinically related non-major bleeding events were compared in different groups.Results A total of 632 patients were included in the study.There was no significant difference in the incidence of major adverse cardiovascular events,major adverse limb events,major bleeding and clinically related non-major bleeding events after the baseline data was balanced by inverse probability of treatment weighting.The results of subgroup analysis were generally consistent with those of the overall study.Conclusion The combination of clopidogrel or cilostazol with rivaroxaban may serve as a novel option for dual antithrombotic therapy in patients diagnosed with lower extremity arteriosclerotic obliterans.
